+

Please type a plus sign (+) inside this box  $\rightarrow$ 

IM.

1634

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE are required to respond to a collection of information unless it displays a valid OMB control number.

Und	der the Paperwork F	Reduction Act of 1995, no	persons are required	d to respond to a collection of in	formation unle	ss it displays a valid OMB control number.
NO.	<u></u>			Application Number	10/552,94	9
				Filing Date	July 27, 2	2006
<i>\$</i>	IRA	NSMITTAL		First Named Inventor	OMARY,	M. BISHR
**		FORM		Group Art Unit	1634	
	(to be used for all correspondence after initial filing)			Examiner Name	Unassign	ned
Total Number of Pages in This Submission				Attorney Docket Number	STAN-297	7
-				ES (check all that apply)	)	
	3 cited re Extension of T Express Abance Information Dis Certified Copy Documents Response to M Incomplete Ap	ched Information tement Form SB08A eferences ime Request donment Request sclosure Statement of Priority Missing Parts/ iplication	(for an   Drawir   Drawir   Licens   Petitio   Provis   Power   Chang   Addres   Termir   Reque	ing-related Papers  n to Convert to a ional Application of Attorney, Revocation e of Correspondence		After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences  Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter  Return postcard
	Response to Missing Parts under 37 CFR 1.52 or 1.53		Remarks			
		SIGNA	TURE OF APPL	ICANT, ATTORNEY, O	R AGENT	
Signing /	Attorney/Agent b.)	PAMELA J. SHERV BØZICEVIC, FIELD	VOOD, 36,677			
Signatur	Signature Mulh 6		Therwood			
Date	Date January 24, 2007					

EXPRESS MAIL LABEL NO. EV 687 639 436 US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail No. EV 687 639 436 US

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Address to:
Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450

Alexandria, VA 22313-1450

Attorney Docket	STAN-297	
First Named Inventor	OMARY, M. BISHR	
Application Number	10/552,949	
Confirmation No.	1285	
Filing Date	July 27, 2006	
Group Art Unit	1634	
Examiner Name	Unassigned	

Title: "KERATIN 8 AND 18 MUTATIONS ARE RISK FACTORS FOR DEVELOPING LIVER DISEASE OF MULTIPLE ETIOLOGIES"

## Dear Examiner:

This is a Supplemental Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97 is not to be construed as a representation that: (i) a search has been made, (ii) additional information material to the examination of this application does not exist, (iii) the information, protocols, results and the like reported by third parties are accurate or enabling or (iv) any one of the above references constitutes prior art to the present application.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. However, if it is determined that fees are required in connection with the filing of this document, the Commissioner is hereby authorized to charge any necessary fees, or alternatively, credit any overpayment to our Deposit Account No. 50-0815, Order No. STAN-297.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

Date: January 24, 2007

BOZICEVIC, FIELD & FRANCIS LLP 1900 University Avenue, Suite 200 East Palo Alto, California 94303 Telephone: (650) 327-3400

Facsimile: (650) 327-3231

зу: \_

Pamela J. Sherwood Registration No. 36,677

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction of 1995 persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO **Application Number** 10/552,949 Filing Date July 27, 2006 SUPPLEMENTAL OMARY, M. BISHR First Named Inventor INFORMATION DISCLOSURE 1634 Art Unit STATEMENT BY APPLICANT Examiner Name Unassigned (use as many sheets as necessary) **STAN-297** Sheet 1 Attorney Docket Number

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
		IRVINE, A., et al., "Human keratin diseases: the increasing spectrum of disease and subtlety of the phenotype-genotype correlation," (1999) <i>British Journal of Dermatology</i> , 140:815-828					
		KU, N., et al., "Mutation of human keratin 18 in association with cryptogenic cirrhosis," (1997) <i>The Journal of Clinical Investigation</i> , 99(1):19-23					
		GENBANK ACCESSION NO. NM_002273					

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.